Interpace Biosciences, Inc. announced that On January 14, 2020, the Board adopted resolutions to appoint the Investors’ designees to the Board upon the Closing. On January 15, 2020, effective immediately upon the Closing, Ampersand re-designated Eric Lev (a Partner at Ampersand Capital Partners) and Robert Gorman to the Board as a Class I and Class II director, respectively, and 1315 Capital designated Edward Chan (an employee of 1315 Capital Management, LLC) to the Board as a Class II director, who were each thereby appointed and elected to the Board. As a Class I director, Mr. Lev will serve until the Company’s 2022 annual meeting of stockholders and, as Class II directors, Messrs. Gorman and Chan will serve until the Company’s 2021 annual meeting of stockholders, or, in each case, until their respective successors are elected and qualified, or until their earlier death, resignation or removal. Messrs. Chan, Gorman and Lev serve on the Board as non-employee directors.